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Abstract
Background: Vivax malaria remains a major cause of morbidity in the subtropics. To undermine the stability of the disease,
drugs are required that prevent relapse and provide reservoir reduction. A 14-day course of primaquine (PQ) is effective but
cannot safely be used in routine practice because of its interaction with glucose-6-phosphate dehydrogenase (G6PD)
deficiency for which testing is seldom available. Safe and effective use of PQ without the need for G6PD testing would be
ideal. The efficacy and safety of an 8-week, once weekly PQ regimen was compared with current standard treatment
(chloroquine alone) and a 14-day PQ regimen.
Methods and Principal Findings: 200 microscopically confirmed Plasmodium vivax patients were randomly assigned to
either once weekly 8-week PQ (0.75mg/kg/week), once weekly 8-week placebo, or 14-day PQ (0.5mg/kg/day) in North West
Frontier Province, Pakistan. All patients were treated with a standard chloroquine dose and tested for G6PD deficiency.
Deficient patients were assigned to the 8-week PQ group. Failure was defined as any subsequent episode of vivax malaria
over 11 months of observation. There were 22/71 (31.0%) failures in the placebo group and 1/55 (1.8%) and 4/75 (5.1%)
failures in the 14-day and 8-week PQ groups, respectively. Adjusted odds ratios were: for 8-week PQ vs. placebo-0.05 (95%CI:
0.01-0.2, p,0.001) and for 14-day PQ vs. placebo-0.01 (95%CI: 0.002-0.1, p,0.001). Restricted analysis allowing for a post-
treatment prophylactic effect confirmed that the 8-week regimen was superior to current treatment. Only one G6PD
deficient patient presented. There were no serious adverse events.
Conclusions: A practical radical treatment for vivax malaria is essential for control and elimination of the disease. The 8-
week PQ course is more effective at preventing relapse than current treatment with chloroquine alone. Widespread use of
the 8-week regimen could make an important contribution to reservoir reduction or regional elimination where G6PD
testing is not available.
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Introduction
Plasmodium vivax is a common cause of malaria in the subtropics.
Estimates put the global burden at 70–80 million cases per year
[1]. Outside Africa, the disease accounts for more than 50% of all
malaria cases, and in Asia it is the major cause of malaria
morbidity [2]. Although P. vivax causes relatively few deaths there
is increasing evidence suggesting that severe and life-threatening
complications are more common than previously thought [3]. P.
vivax has major deleterious effects on development and economic
performance both at individual and national levels [4]; those in
endemic areas may have 10–30 episodes of vivax malaria in the
course of childhood or working life each resulting in 5–15 days
absence from work or school.
Conventional transmission control methods targeting the
mosquito vector are imperfect owing to the infectious reservoir;
dormant hypnozoites in the liver produce episodes of relapse for
several years after initial infection [5]. Relapses from hypnozoites
coincide with the seasonal abundance of the vector and it is this
pattern of relapse which gives the disease its stability in subtropical
areas where transmission by mosquitoes is seasonal [6]. Most vivax
cases experience relapse and each initial infection typically causes
5–6 subsequent episodes if radical treatment is not administered.
Hence a significant proportion of the burden of vivax malaria can
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be attributed to relapses rather than to infections resulting from
transmission [7]. Despite this, there is currently no widely available
safe and effective radical cure. In most malaria endemic areas
glucose-6-phosphate dehydrogenase (G6PD) deficiency, a herita-
ble enzyme deficiency, is common. For example, in Pakistan and
Afghanistan, where P.vivax is the predominant species [8], the
prevalence of G6PD deficiency varies between ethnic groups and
is estimated at 2–10% in the general population [9,10].
Administration of a 14-day course of primaquine (PQ) (the only
recommended regimen that can eliminate the hypnozoite
reservoir) to G6PD deficient individuals is contraindicated due
to the risk of haemolysis [11].
A truncated 5-day course of PQ for vivax malaria is used
commonly in South Asia to reduce the risk of haemolysis and
enhance adherence to treatment [12]. Evidence from Pakistan and
India demonstrates that the 5-day PQ course is ineffective at reducing
relapse rates [13,14]. One recent review concludes that 5-day PQ is
no better than chloroquine alone at radical cure [15]. A study
comparing relapse rates in treatment groups that were supervised and
unsupervised when treated with 14-day PQ indicated that relapse
prevention was similar between the two groups suggesting compa-
rable treatment adherence [7]. However, use of the 14-day course is
only recommended where the G6PD status of the individual is known
and where adherence can be assured [11]. It is for this reason that the
drug is not more widely available [9] since G6PD testing of cases is
impractical in most low-resource settings owing to lack of funds,
equipment and/or expertise.
Studies from the 1960s provide evidence suggesting that
successful PQ therapy is not a function of the length the treatment
course, nor of the concentration of drug, but of the total dosage
administered. Alving et al [16] administered PQ over 7 days,
14 days, and 8 weeks to African Americans. Each regimen equally
prevented relapse in experimentally infected vivax malaria.
Extending the course length seems to reduce the risk of
haemolysis; Brewer and Zarafonetis [17] showed (in African
variant G6PD deficiency) that 8 deficient individuals given 8-week
PQ (total dose 410mg) showed no clinical signs of haemolysis.
Subjects (n = 8) given PQ twice weekly showed more marked
evidence of haemolysis. Further evidence suggests that the
haemolytic effects of PQ in G6PD deficient individuals are not
produced by the drug itself, but by one or more of its many
metabolites [18,19]. Little is known about the pharmacokinetics
and haemolytic potential of the various metabolites [20,21].
However, by extending the time between PQ challenges clearance
of haemotoxic agents (drug metabolites) will be more nearly
complete than in shorter courses involving repeated daily dosing.
The haemolysis seen in shorter courses (5–7 days) is often self-
limiting and there is some evidence that erythropiosis feedback
mechanisms up-regulate production of red cells in response to
haemolytic challenge once acute malaria is treated [22]. Older
erythrocytes are more susceptible to oxidative stress precipitated
by PQ challenge and, in concert with the infection, results in a
younger and more robust circulating population. The extended
course could be safer in G6PD deficient individuals as a result of
these inherent safeguards.
The aim of the study was to test whether an 8-week PQ regimen
is effective at radical cure without the associated risk of haemolysis
in G6PD deficient individuals. This regimen may be appropriate
for deployment in resource-poor settings where G6PD testing is
unavailable. It was compared to current standard treatment
(chloroquine) given with 8-week placebo and to a regimen known
to be effective (chloroquine plus 14-day PQ). Since treatment with
chloroquine alone is current standard treatment, superiority of the
8-week course over placebo was the primary comparison.
Methods
Location
The study was conducted in Adizai, Baghicha and Khagan
villages, close to Peshawar, Northwest Frontier Province, Pakistan
where Afghan refugees have been resident for more than 20 years.
Malaria transmission is seasonal and predominantly due to P. vivax
(85–95% of cases) [6]. The villages contain Basic Health Units
(BHU) run by NGOs, providing free primary health care services
to the populations of the villages. Malaria control in the villages
was supported by a vertical control program implemented by the
NGO HealthNet-TPO and funded by UNHCR. Amongst other
services, the control program provides free quality assured
microscopy and treatment services for all residents. Local vivax
malaria treatment policy is to treat with chloroquine alone while
falciparum malaria (now constituting less than 5% of annual cases)
is treated with sulfadoxine-pyrimethamine and artesunate.
Ethical approval for the study was granted by the Pakistan
Medical Research Council Committee on Bioethics and the
London School of Hygiene and Tropical Medicine ethics
committee. Permission was also obtained from local government
agencies and the United Nations High Commissioner for
Refugees. The study was prospectively registered at clinicaltrials.-
gov (number: NCT00158587). Sponsors and funding agencies
(UNDP/World Bank/WHO Special Program for Research in
Tropical Diseases; Gates Malaria Partnership) had no role in study
design; collection, analysis, and interpretation of data; writing of
the paper; or decision to submit for publication.
Patient Enrolment and Follow-up
Patients attending the basic health units with symptoms
compatible with malaria had Giemsa stained thick and thin blood
films obtained by finger prick and examined by trained
microscopists. Those diagnosed with P. vivax infection were asked
to participate in the study following informed consent and if they
met the inclusion and exclusion criteria. Consent was obtained in
writing by patients or their guardians, and in the case of those
unable to read was witnessed by a literate person. Inclusion criteria
were: Patients diagnosed with P. vivax parasitaemia at study BHUs;
Patients over 3 years of age; Patient permanently resident in the
village. Exclusion criteria were: pregnancy or lactation; severe
clinical anaemia (,7g/dl); P. falciparum and/or P. vivax (mixed
infections); intake of any antimalarial drug in the 2 weeks prior to
consultation; patients unavailable for the duration of follow up
(11 months); patients with concomitant infections or disease likely
to mask treatment response.
The study was designed as an open label, randomised, placebo
controlled study. Patients were randomly allocated to one of the
three treatment groups by study staff in the clinic once informed
consent was received and inclusion/exclusion criteria assessed. For
practical reasons, two randomisation methods were used. In
Baghicha and Khagan villages, patients were randomised by
household, whereas in Adizai randomisation was at the individual
level. Randomisation lists for each village were generated using a
random number list (MS Excel, Microsoft Corp., Seattle, USA) by
staff not involved in patient recruitment. Patients were randomised
on enrolment by study staff in the BHUs based on house number
or sequential patient numbers, depending on the study site.
All patients were treated with initial 3-day chloroquine (25 mg/
kg, in divided doses over 3 days) for acute disease. This was
accompanied by either supervised weekly placebo once per week for
8 weeks; supervised PQ treatment, daily for 14 days (0.5mg/kg per
day); or supervised PQ once per week for 8 weeks (0.75mg/kg per
week). All patients were tested for G6PD deficiency at enrolment
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using a colorimetric test (Sigma Diagnostics, Poole, UK). Those
with G6PD deficiency were not randomised, but assigned to the 8-
week PQ group in order to follow closely to assess safety.
Patients received directly observed treatment according to the
dosing schedule for each treatment group. Each patient was given
an appointment card and if the patient was not present on the
morning of their scheduled dose they were visited in the afternoon
at their home. If the patient was not present they were treated on
the next day. If they were absent on this second day, they were
counted as losses to follow-up. Each dose was recorded with a
signature or finger print of the patient. Patients were monitored
during the eight weeks of treatment and for nine additional
months by active surveillance (being visited in their homes every
two weeks) and passively on presentation at the basic health centre.
Patients presenting at the basic health unit with suspected
treatment failure (febrile illness) were assessed by thick and thin
blood smear. If positive they were classified as a treatment failure
and re-treated with the original treatment given at enrolment.
Blood slides were double read by two independent microscopists,
blinded to the others result.
Statistical Issues
The primary outcome was the occurrence of any episode of
microscopically confirmed vivax malaria over the 11 month
observation period which classified the patient as a treatment
failure. Sample size estimation was based on the assumption of
32% and 49% failure in treated (14-day PQ) and untreated
individuals, as recorded previously in other studies over a 9 month
post treatment follow-up [7,13]. Allowing for 15% loss to follow-
up a sample size of 212 per treatment arm was required to detect
this difference with 90% power at the 95% confidence level. The
incidence of malaria was significantly lower than that seen in
previous years leading to lower-than-expected enrolment rates.
This led to a revision of sample size following an unscheduled
interim analysis conducted in June/July 2006 with the aim of
determining whether to halt the trial for futility as it would be
unable to hit initial sample size targets because of the low malaria
incidence. It was based on data from 88 patients enrolled in
Khagan and Baghicha camps who had completed the 11 month
observation period. The decision was made that the public health
importance of being able to detect a larger difference than that
initially calculated remained high, and that the trial should be
completed aiming to detect the larger difference of 5% failure in
the 8 week PQ group and 30% in the placebo group (ie unable to
exclude a smaller difference). A revised sample size of 66 per
treatment arm (allowing 10% loss to follow-up) gave a power of
90% at the 95% confidence level to detect this difference. The
study was not powered to show equivalence between the 14-day
and 8-week PQ arms.
Analysis was conducted on an intention-to-treat basis. In
addition to the primary outcome, secondary outcome variables
included the number of subsequent episodes and anaemia rates
during and up to 2 weeks post-treatment as well as any notable
adverse events. Univariate logistic regression analysis using the
primary outcome provided crude odds ratios (OR). Potential
confounders (sex, age-group and village) were identified on an a
priori basis and were included in multivariate analysis. Each
treatment group was compared in turn to assess superiority (or
otherwise) using logistic regression analysis, adjusting for potential
confounders. Kaplan-Meier survival analysis using time to first
relapse as the endpoint was used to calculate cumulative
probability of treatment failure (i.e. having no further episode of
malaria). Losses to follow-up were treated as censured data in the
analysis. Data was recorded by trained health workers on patient
record forms, double entered using Excel XP (Microsoft Corp,
Seattle, USA) and analysed using STATA v10.0 (Stata Corp,
College Station, TX, USA).
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Results
200 patients were recruited from 13th September 2004 until 17th
July 2006. Follow-up was completed on 16th June 2007. The
number (%) recruited into the study at each site was: Adizai 100
(50.0%), Baghicha 79 (39.5%), and Khagan 21 (10.5%). Ten
(5.0%) were either lost to follow-up (9) or withdrawn owing to
protocol violation (1). Seventy one (35.5%) patients were enrolled
to 8-week placebo, 55 (27.5%) to 14-day PQ and 74 to 8-week
placebo (37.0%). Figure 1 shows patient through-put during the
observation period and Table 1 shows enrolment characteristics.
There were 22/71 (31.0%) failures in the placebo group and 1/
55 (1.8%) and 4/75 (5.1%) failures in the 14-day and 8-week PQ
groups respectively, giving rates of failure (per 1000/pers months) of
37.3 (95%CI: 24.6–56.6), 1.7 (0.2–12.0) and 5.5 (2.1–14.7),
respectively. Treatment group and village were independently
associated with treatment failure, with highest failure rates recorded
in the placebo group and in Adizai village (Table 2). Sex was not
associated with treatment failure. Multivariate logistic regression
analysis of treatment outcome, adjusting for sex, age-group and
village was conducted to compare each group in turn (Table 3). By
this analysis the 8-week PQ regimen was superior to placebo (AOR
0.05 [95%CI–0.01-0.2], p,0.001), as was the 14-day PQ regimen
(AOR 0.01 [95%CI–0.002-0.1], p,0.001). Cure rates for the
14 day PQ appear slightly higher than for 8 week PQ regimens
(AOR 3.8 [95%CI–0.4-36.7] p= 0.3), however the study was
insufficiently powered to demonstrate equivalence or superiority.
Since a prophylactic effect of PQ administered over the 8 week
treatment period may confound true failures, two restricted
analyses were conducted which included only those who had
failed treatment in the post treatment period. The first was
restricted to failures occuring in months 2–11. The second took
account of the time the drug was potentially providing a
prophylactic effect, and included the period of administration of
active drugs plus an additional 30 day period, post-treatment. For
this analysis data were censured at 33 days for the placebo group,
44 days for the 14 day PQ group and 91 days for the 8 week PQ
group (Table 3). The data was also censured at 244 days post
restriction period to give equal periods of observation. During the
2–11 month period there were 11/60 (18.3%) failures in the 8-
week placebo group; 1/55 (1.8%) in the 14-day PQ group; and 4/
74 (5.4%) failures in the 8-week PQ group. When compared by
treatment group and adjusted for age, sex and refugee village, both
8-week and 14-day PQ were superior to 8-week placebo (AOR
0.1, 95% CI: 0.03-0.5, p,0.0001) and (AOR 0.03, 95%CI: 0.003-
0.3, p,0.0001), respectively (table 3). After treatment plus
30 days, over the 244 day observation period, results differed
marginally (table 3).
Table 4 shows the number of episodes of malaria recorded
during the observation period. In the placebo group, 5 additional
episodes of malaria were recorded in one patient, whereas only
single episodes were recorded in any of the PQ treated patients.
Median time to first episode was, 63 days (range 36–322 days)
(n = 22) in the placebo group; 285 days (n = 1) in the 14-day group
and 125 days (range 113–158) (n = 4) in the 8-week group. There
were too few failures for reliable statistical assessment of
differences in the median time to failure. Table 5 shows the
Primaquine and Vivax Malaria
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frequency of first relapse during the 2 month period of treatment
and then at 3 month intervals during the follow-up period. In the
8-week placebo group 11/22 (50.0%) of failures were recorded
during the first two months. Cumulative probability of treatment
failure for each group over the full 11 month observation period
was 35.2% (95%CI: 25.3–47.5%) in the placebo group, 3.6%
(95%CI: 0.9–13.8%) in the 14-day and 13.5% (95%CI: 7.5–
23.7%) in the 8-week PQ group (long-rank test for equality of
survivor functions-Chi2 = 22.1, p,0.001) (Figure 2). Figure 3
shows the cumulative probability of treatment failure for the
restricted analysis, which excluded all failures occurring during the
period of treatment (0–8 weeks).
There were no reported serious or notable non-serious adverse
events and all treatments were well tolerated. Only 1 G6PD
deficient patient, a 13 year-old male, was detected during this trial.
On days 7 and 14 (prior to the second and third PQ doses), Hb in
this individual fell below the confidence limits of the mean Hb in
G6PD normal females aged 12–14 (n = 13). On day 7 Hb was
10.0g/dl vs 12.6g/dl (95%CI: 11.8–13.4) and on day 14 Hb was
10.6 vs 12.6 (95%CI: 12.0–13.3). By day 21 (prior to the fourth
dose) Hb in the patient was within the limits of age and sex
matched G6PD normal individuals (hb = 12.7 vs 12.6 [95%CI:
11.8–13.5]). The haemoglobin profile of the three treatment arms
in the whole sample did not differ. No patient became seriously
anaemic (Hb,7.0 g/dl), and no observed anaemia was clinically
significant.
Discussion
The 8-week PQ regimen in combination with chloroquine is
effective at curing acute vivax malaria and preventing relapses.
Over a period of 11 months, new episodes of vivax malaria were
more frequent in the group administered with placebo than in
either PQ treated group and the superiority of 8-week PQ over
chloroquine alone is demonstrated. The analysis provides
information on the effect of an initial PQ treatment as well as
repeated doses. The use of incidence of first relapse as the primary
outcome provides evidence that the 8-week course is superior to
Table 1. Enrolment characteristics of study sample, by
treatment group.
8-week
Placebo 14-day PQ 8-week PQ
Number 71 55 74
Number lost to follow-up 3 (4.2%) 1 (1.8%) 6 (8.1%)
Study Site
Adizai 27 30 43
Baghicha 33 23 23
Khagan 11 2 8
% Male 58.6 43.6 48.0
Median Age, yrs [Range] 9 [4–50] 10 [4–45] 10 [4–80]
Median Weight, Kg [Range] 25 [12–67] 24 [8–70] 29 [11–66]
Mean Hb on Day 0, g/dl [SD] 12.0 [1.7] 12.6 [1.9] 12.6 [1.8]
N (%) anemic (Hb,10.0) 10 (14.1) 2 (3.6) 7 (9.5)
doi:10.1371/journal.pone.0002861.t001
Table 2. Number (%) with treatment failure in each
treatment group over the 11 month observation period, by
sex, age group and village.
8-week Placebo 14-day PQ 8-week PQ
All 22/71 (31.0) 1/55 (1.8) 4/74 (5.1)
Male 10/41 (24.4) 0/24 2/35 (5.7)
Female 12/29 (41.4) 1/31 (3.2) 2/38 (5.3)
Age Group
3–10 15/46 (32.6) 1/30 (3.3) 4/38 (10.5)
11–20 7/20 (35.0) 0/19 0/23
.20 0/5 0/6 0/13
Village
Adizai 18/27 (66.7) 1/30 (3.3) 4/43 (9.3)
Baghicha 4/33 (12.1) 0/23 0/23
Khagan 0/11 0/2 0/8
doi:10.1371/journal.pone.0002861.t002
Figure 1. Patient flow through the trial at enrolment, end of treatment period (8 weeks) and end of follow-up (11 months).
doi:10.1371/journal.pone.0002861.g001
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placebo in prevention of episodes of relapse when given as a single
course. Patients who presented with a second (or further) episodes
were treated with the same regimen as at enrolment. Incidence of
recurrent episodes was lower in both the PQ groups; only one
recurrent episode was seen in any patient, whereas up to five
recurrent episodes were seen in one patient in the placebo group.
The restricted analysis, which used two approaches to exclude
failures during the treatment period (when any prophylactic effect
would be seen), confirms that both PQ treated groups are superior
to placebo in preventing recurrent episodes. The pattern of failure
in the 8-week PQ group, where failures occurred between two and
three months post treatment, provides possible evidence of a
prophylactic effect; the timing and pattern of the failures matches
that of the placebo arm once the drug (and metabolites) have
cleared. It could be, therefore, that failures (relapses) are simply
Table 3. Univariate and multivariate logistic regression analysis for treatment failure comparing each group. 95% confidence
intervals in parenthesis.
Full study period (11 months
observation)
Restricted to failures occurring
from 2–11 months2
Restricted to failures occurring
from the end of treatment+30 days3
OR AOR1 OR AOR1 OR AOR1
Placebo vs. 8-week PQ 0.1 (0.04–0.4)4 0.05 (0.01–0.2) 4 0.3 (0.08–0.9)5 0.1 (0.03–0.5) 4 0.4 (0.2–0.7) 4 0.3 (0.1–0.5) 4
Placebo vs. 14-day PQ 0.04 (0.005–0.3) 4 0.01 (0.002–0.1) 4 0.08 (0.01–0.6) 4 0.03 (0.003–0.3) 4 0.05 (0.006–0.4) 4 0.02 (0.002–0.1) 4
14-day PQ vs. 8-week PQ 3.1 (0.3–28.4) 3.8 (0.4–36.7) 3.3(0.4–30.5) 4.2 (0.4–41.3) 3.3 (0.4–30.5) 4.2 (0.4–41.3)
1Adjusted odds ratios (AOR) adjust for refugee village, sex and age.
2Restricted analysis excludes all failures during treatment period (months 0–1).
3Restricted analysis excludes all failures occurring before 33 days for placebo group, 44 days for 14 day PQ group and 91 days for 8 week group. Time under
observation is censured at 244 days post restriction period to give equal follow-up period.
4p,0.001
5p,0.01
doi:10.1371/journal.pone.0002861.t003
Table 4. Frequency of subsequent episodes of malaria in
each treatment group over 11 month observation period,
number (%).
Number of Subsequent
Malaria Episodes 8-week Placebo 14-day PQ 8-week PQ
0 46 (67.7) 53 (98.2) 67 (93.1)
1 12 (17.7) 1 (1.9) 4 (5.6)
2 6 (8.8) 0 0
3 3 (4.4) 0 0
4 0 0 0
5 1 (1.5) 0 0
doi:10.1371/journal.pone.0002861.t004
Table 5. Number (%) with treatment failure during different
stages of follow-up over the 11 month observation period.
0–2
months* a
3–5
monthsb
6–8
monthsns
9–11
monthsns
8-week
Placebo
11/71 (15.5) 6/60 (10.0) 1/54 (1.9) 4/53 (7.6)
14-day PQ 0/55 0/55 0/55 1/55 (1.8)
8-week PQ 0/74 3/74 (4.1) 1/71 (1.4) 0/70
*During 8-week treatment period;
aChi2 = 18.3, df = 2, p,0.001;
bChi2 = 5.8, df = 2 p= 0.054;
nsNot significant.
doi:10.1371/journal.pone.0002861.t005
Figure 3. Kaplan Meier survival analysis, by treatment group,
restricted to post-treatment period (months 2–11).
doi:10.1371/journal.pone.0002861.g003
Figure 2. Kaplan Meier Survival Analysis, by treatment group,
over 11 months of observation.
doi:10.1371/journal.pone.0002861.g002
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delayed by a prophylactic effect of 8-week PQ therapy. If this were
the case, however, failed patients treated with PQ for an additional
eight weeks would be expected to have differing failure rates when
censured at different time-points to account for the prophylactic
effect. This effect is not seen; none of the 8-week PQ group had
second relapse episodes (table 4). The periodicity of initial failures
in the placebo group also support this; without radical treatment
with PQ, failures occur in two distinct periods–between 0–
3 months post treatment and between 6–9 months post treatment
(table 5 and figures 2 and 3), where this is not seen in the 8-week
PQ group. The 9 month follow up of each patient suggests that
both PQ regimens eliminated the hypnozoite reservoir. Even
though some PQ metabolites have long half-lives [18], 9 months
should be sufficient to allow for clearance of the drug and it’s
metabolites. This makes it unlikely that the drugs are simply
suppressing emergence of merozoites from latent hypnozoites and
likely that the 8-week PQ course is eliminating hypnozoites and
providing radical cure.
A recent meta-analysis of 14-day PQ trials describes regional
variation in PQ efficacy in India, Brazil and Thailand [23]. In
untreated patients, relapse rates up to 80% were noted in
Thailand. The median relapse rate in treated groups in India
was ,10% (range 7%–21%) whereas in untreated groups it was
somewhat higher, at 37%. Relapse rates in all treated groups (in all
three countries) was reduced by 14-day PQ therapy. This analysis
did not account for background transmission (causing re-infection),
which may account for some of the variation seen between
regions. It is not possible to distinguish those episodes that are true
relapses from those that are re-infections; there is no reliable way
of differentiating between the two [24]. Two comparable studies in
this region (and, indeed, in these same villages) have shown failures
in 14-day PQ groups at 32% and 19% conducted in 1996 and
2000–1, respectively, using 9 month observation periods [7,13].
However, the villages where the present study was conduced had
markedly lower transmission rates at the time; the incidence of
vivax cases per annum was,1% in Baghicha/Kagan and 3.3% in
Adizai during 2004 to 2007, a 75% reduction compared to 2000–1
when the last study [7] was conducted. Almost all of the cases
detected in the population of the villages were enrolled, and thus
around 50–60% of patients received anti-relapse therapy. Against
the backdrop of very low transmission in this study, the differences
seen compared to the earlier trials conducted in the same villages
are probably attributable to a marked reduction in the number of
transmission (re-infection) cases rather than to changes in drug
sensitivity. The low transmission during the study period provides
circumstantial evidence for PQ susceptibility in this region. PQ
resistant vivax has been reported elsewhere in Asia [25] where it is
thought to have developed through the exposure of vivax to the
drug when it was widely employed to reduce falciparum
gametocytes [26]. In Pakistan and Afghanistan, 5-day PQ for
vivax radical treatment, as well as PQ for falciparum gametocytes
had been used for many years (although both policies were
abandoned in the refugee camps in 2001) despite which vivax
appears to remain highly sensitive. Vivax also remains highly
susceptible to chloroquine in this region [27] in contrast to other
areas (e.g. Papua) [28].
Efficacy and safety data on 8-week PQ is scarce, based on small
sample sizes with no comparison group [16,17]. The present study
is the first randomised controlled trial evidence for the efficacy of
the regimen, and although effective and safe in this sample,
conclusions on safety in G6PD deficient patients in general cannot
be drawn. The prevalence of G6PD deficiency in our study
population was too low to make comparisons. The 5-day PQ
course is frequently used in the region yet there are no reports of
serious G6PD related adverse events either in the literature or
anecdotally following this regimen. The sole G6PD deficient
patient showed a slight drop in haemoglobin which was not
clinically significant. This may indicate that in this population,
G6PD deficiency is less of a risk to treatment with 8 week PQ than
currently assumed. If the eight week regimen is to be considered as
policy, assessment of the safety profile in G6PD deficient patients
will be needed.
An important issue in broadening access to 8-week PQ therapy is
adherence to the regimen. Ensuring adherence to a 2 month, once
weekly regimen will require proven interventions at the delivery
level. Unsupervised 14-day PQ, accompanied by strong health
education messages was equally effective to supervised therapy in
terms of treatment outcome amongst Afghan refugees in Pakistan
[7]. In Thailand, poor adherence rates to the 14 day course is
considered to be responsible for poor cure rates, whereas a high dose
(60mg per day) 7 day regimen was shown to be efficacious in G6PD
normal individuals over 28 days of follow-up [29]. However, this
observation period is short, and our study shows that longer periods
of follow up are desirable before coming to firm conclusions on
radical cure can be made. However, the contrast between
adherence in these differing settings indicates that commonly held
concerns or assumptions about adherence to treatment are variable
and can be modified. A number of studies have shown that
adherence to treatment can be enhanced by relatively simple and
inexpensive measures such as blister packaging, aides memoir,
health education and improved provider knowledge [30]. These
interventions may be similarly appropriate for long-course PQ but
will require evaluation before they are taken to scale.
Since the idea of malaria elimination (or eradication) has again
reached prominence [31], efforts to improve radical treatment of
vivax malaria are required. In the absence of easily administered
and widely available G6PD testing, the 8-week course of PQ
should be further explored as a tool in preventing recurrent
episodes of acute malaria and reducing the infectious reservoir.
Widespread use of 8 week PQ has the potential to have dramatic
effects on the global burden of vivax malaria.
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